Show simple item record

dc.contributor.authorPeek, G
dc.contributor.authorOlsen, CM
dc.contributor.authorBaade, P
dc.contributor.authorYoulden, DR
dc.contributor.authorAitken, JF
dc.contributor.authorGreen, Ad�le C
dc.contributor.authorKhosrotehrani, K
dc.date.accessioned2020-04-22T07:25:12Z
dc.date.available2020-04-22T07:25:12Z
dc.date.issued2020en
dc.identifier.citationPaz-Ares L, Spira A, Raben D, Planchard D, Cho BC, Ozguroglu M, et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol. 2020.en
dc.identifier.pmid32246965en
dc.identifier.doi10.1016/j.jaad.2020.03.076en
dc.identifier.urihttp://hdl.handle.net/10541/622933
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.jaad.2020.03.076en
dc.titleSurvival in patients with multiple primary melanomas: systematic review and meta-analysisen
dc.typeArticleen
dc.contributor.departmentQueensland Skin and Cancer Foundation, Queensland Institute of Dermatology, South-Brisbane, Queensland, Australia.en
dc.identifier.journalJournal of the American Academy of Dermatologyen
dc.description.noteen]
refterms.dateFOA2020-04-22T11:40:52Z


Files in this item

Thumbnail
Name:
32246965.pdf
Size:
399.7Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record